Hosted on MSN6d
Allurion shares soar 77% after sharing plans for GLP-1RA combo trial
Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.
Investor's Business Daily on MSN6d
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Allurion Technologies stock soars on clinical study announcement
Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during ...
Wall Street Breakfast Podcast: Allurion Soars On Balloon And GLP-1 Study Plans
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
US Stocks Set To Open Lower After Bank Of Japan Rate Hike: Analyst Recommends 'Overweight' Equities Despite Negative Market Breadth
U.S. stock futures fell on Friday following a 25 basis point rate hike by the Bank of Japan. Futures of all four indices declined.